The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View

Autor: Tambaro FP, De Novellis D, Wierda WG

Publikováno v: Journal of Experimental Pharmacology, Vol Volume 13, Pp 923-935 (2021)

Francesco Paolo Tambaro,1 Danilo De Novellis,1,2 William G Wierda3 1Unità Operativa di Trapianto di Midollo Osseo e Servizio Trasfusionale, Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon, Napoli, Italy; 2Department of Precision Medici

Externí odkaz: https://doaj.org/article/986d7161af1b4df1b23594f692f378f6

Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with IGHV, ZAP-70, and MRD.

Autor: Kim E; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Chen SS; The Feinstein Institute for Medical Research, Manhasset, New York, United States., Sivina M; MD Anderson Cancer Center, Houston, Texas, United States., Hwang H; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Huang X; University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Ferrajoli A; the University of Texas, M.D. Anderson Cancer Center, Houston, Texas, United States., Jain N; M.D. Anderson Cancer Ctr. University of Texas, Houston, Texas, United States., Wierda WG; University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States., Wodarz D; University of California, Irvine, United States., Chiorazzi N; The Feinstein Institutes for Medical Research, Manhasset, New York, United States., Burger JA; University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States.

Publikováno v: Blood [Blood] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23.

Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trial.

Autor: Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH., Cheah CY; Linear Clinical Research, Sir Charles Gairdner Hospital, University of Western Australia, Perth, Australia., Coombs CC; Division of Hematology and Oncology, Department of Medicine, University of California, Irvine, Orange, CA., Shah NN; Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Wierda WG; MD Anderson Cancer Center, Houston, TX., Patel MR; Florida Cancer Specialists, Sarah Cannon Research Institute, Sarasota, FL., Lamanna N; Columbia University Irving Medical Center, NewYork-Presbyterian, New York, NY., Tsai DE; Loxo@Lilly, Indianapolis, IN., Nair B; Loxo@Lilly, Indianapolis, IN., Wang C; Eli Lilly and Company, Indianapolis, IN., Zhao X; Loxo@Lilly, Indianapolis, IN., Liu D; Eli Lilly and Company, Indianapolis, IN., Radtke D; Eli Lilly and Company, Indianapolis, IN., Chapman S; Eli Lilly and Company, Indianapolis, IN., Marella N; Loxo@Lilly, Indianapolis, IN., McNeely SC; Loxo@Lilly, Indianapolis, IN., Brown JR; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

Publikováno v: Blood [Blood] 2024 Sep 26; Vol. 144 (13), pp. 1374-1386.

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.

Autor: Wierda WG; The University of Texas, MD Anderson Cancer Center, Houston, TX, USA. Electronic address: wwierda@mdanderson.org., Shah NN; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA., Cheah CY; Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, WA, Australia., Lewis D; Plymouth Hospitals NHS Trust, Derriford Hospital, Plymouth, UK., Hoffmann MS; The University of Kansas Cancer Center, Kansas City, KS, USA., Coombs CC; University of California Irvine Health, Chao Family Comprehensive Cancer Center, Orange, CA, USA., Lamanna N; Herbert Irving Comprehensive Cancer Center, New York-Presbyterian Hospital, Columbia University Medical Center, New York, NY, USA., Ma S; Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA., Jagadeesh D; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA., Munir T; Department of Haematology, St James's University Hospital, Leeds, UK., Wang Y; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Eyre TA; Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Centre, Oxford, UK., Rhodes JM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., McKinney M; Duke Cancer Institute, Durham, NC, USA., Lech-Maranda E; Institute of Hematology and Transfusion Medicine, Warsaw, Poland., Tam CS; Alfred Hospital and Monash University, Melbourne, Australia., Jurczak W; Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland., Izutsu K; National Cancer Center Hospital, Tokyo, Japan., Alencar AJ; Sylvester Comprehensive Cancer Center, University of Miami, Miller School of Medicine, Miami, FL, USA., Patel MR; Florida Cancer Specialists and Sarah Cannon Research Institute, Sarasota, FL, USA., Seymour JF; Alfred Hospital and Monash University, Melbourne, Australia., Woyach JA; The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA., Thompson PA; Alfred Hospital and Monash University, Melbourne, Australia., Abada PB; Loxo Oncology, Indianapolis, IN, USA., Ho C; Loxo Oncology, Indianapolis, IN, USA., McNeely SC; Loxo Oncology, Indianapolis, IN, USA., Marella N; Loxo Oncology, Indianapolis, IN, USA., Nguyen B; Loxo Oncology, Indianapolis, IN, USA., Wang C; Eli Lilly, Indianapolis, IN, USA., Ruppert AS; Eli Lilly, Indianapolis, IN, USA., Nair B; Loxo Oncology, Indianapolis, IN, USA., Liu H; Loxo Oncology, Indianapolis, IN, USA., Tsai DE; Loxo Oncology, Indianapolis, IN, USA., Roeker LE; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Ghia P; Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2024 Sep; Vol. 11 (9), pp. e682-e692. Date of Electronic Publication: 2024 Jul 18.

LP-118 is a novel B-cell lymphoma 2 / extra-large inhibitor that demonstrates efficacy in models of venetoclax-resistant chronic lymphocytic leukemia.

Autor: Ravikrishnan J; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Diaz-Rohena DY; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX., Muhowski E; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Mo X; Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH., Lai TH; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Misra S; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Williams CD; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX., Sanchez J; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX., Mitchell A; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Satpati S; Department of Genomic Medicine, MD Anderson Cancer Center, Houston TX., Perry E; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Kaufman T; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Liu C; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX., Lozanski A; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Lozanski G; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Rogers K; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Kittai AS; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Bhat SA; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Collins MC; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Jain N; Department of Leukemia, MD Anderson Cancer Center, Houston TX., Wierda WG; Department of Leukemia, MD Anderson Cancer Center, Houston TX., Lapalombella R; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH., Byrd JC; Department of Internal Medicine, University of Cincinnati, Cincinnati, OH., Tan F; Newave Pharmaceutical Inc., Pleasanton, CA., Chen Y; Newave Pharmaceutical Inc., Pleasanton, CA., Chen Y; Newave Pharmaceutical Inc., Pleasanton, CA., Shen Y; Newave Pharmaceutical Inc., Pleasanton, CA., Anthony SP; Newave Pharmaceutical Inc., Pleasanton, CA., Woyach JA; Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH. Jennifer.Woyach@osumc.edu., Sampath D; Division of Hematopoietic Biology and Malignancy, MD Anderson Cancer Center, Houston TX. DSampath@mdanderson.org.

Publikováno v: Haematologica [Haematologica] 2024 Aug 08. Date of Electronic Publication: 2024 Aug 08.